U.S. Markets open in 5 hrs 25 mins

Alphatec Reports Second Quarter 2019 Financial Results and Corporate Highlights

Full Year 2019 Revenue Guidance Increased 
Following 28% Q2 U.S. Revenue Growth 

CARLSBAD, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2019, and recent corporate highlights.

Second Quarter 2019 Financial Highlights

  • Total net revenue of $27.3 million; U.S. revenue of $26.1 million, up approximately 28% compared to the second quarter of 2018;
  • U.S. gross margin of 72.2%; and
  • Cash and cash equivalents of $18.6 million as of June 30, 2019.

Second Quarter-to-Date Commercial, Product, and Organizational Highlights

  • Enhanced clinical distinction of portfolio with four new commercial releases: the IdentiTi™ TLIF system, the IdentiTi ALIF system, the InVictus™ MIS Fixation System and the InVictus Open Fixation System;
  • Increased contribution from new products to 32% of Q2 2019 U.S. revenue;
  • Expanded percentage of revenue driven by strategic distribution network to 88% of U.S. revenue in Q2 2019 compared to 80% in Q2 2018; and
  • Increased U.S. revenue per distributor by more than 45% and increased U.S. revenue per case by 15% in Q2 2019 compared to Q2 2018.     

“Through the first half of 2019, execution against our strategic commitments has been solid,” said Pat Miles, Chairman and Chief Executive Officer.  “That execution drove the highest rate of quarterly U.S. revenue growth this company has achieved in the past 10 years.  Based upon our performance in the first half of 2019 we are increasing full-year revenue guidance, which speaks to the impact of spine’s new Organic Innovation Machine.  We are just getting started.”

Comparison of Selected GAAP and Non-GAAP Financial Results for the Second Quarter 2019 to Second Quarter 2018

  Three Months Ended   Change
  June 30, 2019   June 30, 2018   $   %
  (unaudited)   (unaudited)        
               
Revenue from U.S. products $ 26,093     $ 20,409     $ 5,684     28 %
Gross profit from U.S. products   18,841       15,462       3,379     22 %
Gross margin from U.S. products   72.2 %     75.8 %        
               
Operating Expenses              
Research and development $ 3,360     $ 2,009     $ 1,351     67 %
Sales, general and administrative   24,568       17,538       7,030     40 %
Litigation-related expenses   1,200       2,234       (1,034 )   (46 %)
Amortization of intangible assets   172       187       (15 )   (8 %)
Transaction-related expenses   -       (62 )     62     (100 %)
Restructuring   -       193       (193 )   (100 %)
Total operating expenses $ 29,300     $ 22,099     $ 7,201     33 %
               
Operating loss $ (10,414 )   $ (6,545 )   $ (3,869 )   59 %
               
Non-GAAP operating loss $ (4,663 )   $ (2,578 )   $ (2,085 )   81 %
               
Non-GAAP adjusted EBITDA $ (3,018 )   $ (989 )   $ (2,029 )   205 %

Revenue from U.S. products for the second quarter 2019 was $26.1 million, up 28% compared to $20.4 million in the second quarter 2018. Revenue growth generated by new product momentum and the strategic distribution channel is increasingly outpacing the continued revenue impacts of transitioning or discontinuing non-strategic distributor relationships.

Gross profit and gross margin from U.S. products for the second quarter 2019 were $18.8 million and 72.2%, respectively, compared to $15.5 million and 75.8%, respectively, for the second quarter 2018. U.S. gross margin was impacted by increased non-cash excess and obsolete write-offs related to legacy products. On a non-GAAP basis, excluding non-cash excess and obsolete charges, U.S. gross margin was 80.6% in the second quarter of 2019, up from 77.5% in the second quarter of 2018.

Total operating expenses for the second quarter 2019 were $29.3 million compared to $22.1 million in the second quarter 2018.  On a non-GAAP basis, excluding restructuring charges, stock-based compensation, transaction-related expenses, litigation-related expenses, restructuring and fair value adjustments, total operating expenses in the second quarter 2019 increased to $25.8 million from $18.5 million in 2018, reflecting increased investments in organic product development to support new product launches and increased selling costs from U.S. revenue growth.

Non-GAAP operating loss which excludes restructuring charges, stock-based compensation, transaction-related expenses, litigation-related expenses, restructuring, fair value adjustments and excess and obsolescence charges, was $4.7 million for the second quarter 2019, compared to a loss of $2.6 million for the second quarter 2018. 

Non-GAAP adjusted EBITDA in the second quarter was a loss of $3.0 million, compared to a loss of $1.0 million in the second quarter 2018. 

For more detailed information on non-GAAP operating expenses, non-GAAP operating loss and non-GAAP adjusted EBITDA, please refer to the table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures,” that follows.

Current and long-term debt includes $45.0 million in term debt and $10.7 million outstanding under the Company’s revolving credit facility at June 30, 2019, with cash and cash equivalents of $18.6 million. In March 2019, the Company closed its expanded credit facility with Squadron Medical Finance Solutions, providing for up to $30 million in additional financing, as needed. During the second quarter 2019, the Company drew $10 million against the credit facility.

Updated 2019 Financial Outlook

Full Year 2019 Previous Updated
  Guidance ($M) YoY Growth Guidance ($M) YoY Growth
U.S. Product Revenue $94 to $98 12% to 17% $100 to $104 20% to 24%
International Supply Agreement $4 to $5 (38%) to (50%) No change No change
Total Revenue $98 to $103 7% to 12% $104 to $109 13% to 19%

Investor Conference Call

ATEC will present the results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At that time, please click here to access the live webcast.  An audiocast of the presentation will be also be available domestically at (877) 556-5251 and internationally at (720) 545-0036. The conference ID number is 6098197.

Non-GAAP Financial Information

To supplement the Company’s financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP U.S. gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc., through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery. ATEC designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma.  The Company markets its products in the U.S. via independent sales agents and a direct sales force.

Additional information can be found at www.atecspine.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include the references to the Company’s revenue and growth outlook, planned commercial launches and product introductions, the Company’s strategy in significantly repositioning the ATEC brand, turning the Company into a growth organization and creating future market disruption, and the Company’s future ability to finance its operations. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the Company’s pipeline; the uncertainties in the Company’s ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for procedures performed using the Company’s products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company’s ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company’s ability to compete with other products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any litigation in which the Company is a defendant; patent infringement claims; claims related to the Company’s intellectual property and the Company’s ability to meet its financial obligations under its credit agreements and the OrthoTec LLC settlement agreement. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Investor/Media Contact:

Tina Jacobsen
Investor Relations
(760) 494-6790
ir@atecspine.com

Company Contact:

Jeff Black
Chief Financial Officer
ir@atecspine.com 

ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
  (in thousands, except per share amounts - unaudited)
                   
                   
    Three Months Ended   Six Months Ended  
    June 30,   June 30,  
      2019       2018       2019       2018    
                   
  Revenues:                
  Revenue from U.S. products $ 26,093     $ 20,409     $ 49,048     $ 39,610    
  Revenue from international supply agreement   1,226       1,633       2,826       3,739    
  Total revenues   27,319       22,042       51,874       43,349    
  Cost of revenues   8,433       6,488       16,420       12,890    
  Gross profit   18,886       15,554       35,454       30,459    
                   
  Operating expenses:                
  Research and development   3,360       2,009       6,829       3,795    
  Sales, general and administrative   24,568       17,538       45,568       34,795    
  Litigation-related expenses   1,200       2,234       3,823       2,814    
  Amortization of intangible assets   172       187       354       364    
  Transaction-related expenses   -       (62 )     -       1,480    
  Gain on settlement   -       -       -       (6,168 )  
  Restructuring expenses   -       193       60       591    
  Total operating expenses   29,300       22,099       56,634       37,671    
  Operating loss   (10,414 )     (6,545 )     (21,180 )     (7,212 )  
  Total other expenses, net   (1,921 )     (1,784 )     (4,040 )     (3,429 )  
  Loss from continuing operations before taxes   (12,335 )     (8,329 )     (25,220 )     (10,641 )  
  Income tax (benefit) provision   71       (1,265 )     102       (1,723 )  
  Loss from continuing operations   (12,406 )     (7,064 )     (25,322 )     (8,918 )  
  Loss from discontinued operations   (30 )     (12 )     (82 )     (74 )  
  Net loss $ (12,436 )   $ (7,076 )   $ (25,404 )   $ (8,992 )  
                   
                   
  Net loss per share, basic and diluted:                
  Continuing operations $ (0.26 )   $ (0.21 )   $ (0.55 )   $ (0.32 )  
  Discontinued operations   (0.00 )     (0.00 )     (0.00 )     (0.00 )  
  Net loss per share, basic and diluted $ (0.27 )   $ (0.21 )   $ (0.55 )   $ (0.33 )  
                   
  Shares used in calculating basic and diluted net loss per share   46,880       34,030       45,957       27,656    
                   
  Stock-based compensation included in:                
  Cost of revenue $ 28     $ 11     $ 56     $ 33    
  Research and development   293       129       533       13    
  Sales, general and administrative   2,030       1,008       3,374       1,721    
    $ 2,351     $ 1,148     $ 3,963     $ 1,767    
                                   


  ALPHATEC HOLDINGS, INC.
  CONDENSED CONSOLIDATED BALANCE SHEETS
  (in thousands)
         
         
    June 30,   December 31,
    2019   2018
    (Unaudited)    
  ASSETS
  Current assets:      
  Cash $ 18,570   $ 29,054
  Accounts receivable, net   13,642     15,095
  Inventories, net   32,605     28,765
  Prepaid expenses and other current assets   10,904     2,380
  Current assets of discontinued operations   225     242
  Total current assets   75,946     75,536
         
  Property and equipment, net   15,090     13,235
  Right-of-use asset   2,170     -
  Goodwill   13,897     13,897
  Intangibles, net   26,054     26,408
  Other assets   222     347
  Noncurrent assets of discontinued operations   53     54
  Total assets $ 133,432   $ 129,477
         
  LIABILITIES AND STOCKHOLDERS' EQUITY
  Current liabilities:      
  Accounts payable $ 8,178   $ 4,399
  Accrued expenses   20,831     22,316
  Current portion of long-term debt   286     3,276
  Current portion of lease liability   1,173     -
  Current liabilities of discontinued operations   538     621
  Total current liabilities   31,006     30,612
         
  Total long term liabilities   64,662     57,688
         
  Redeemable preferred stock   23,603     23,603
  Stockholders' equity   14,161     17,574
  Total liabilities and stockholders' equity $ 133,432   $ 129,477
         


ALPHATEC HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in thousands - unaudited)
                     
      Three Months Ended   Six Months Ended  
      June 30,   June 30,  
        2019       2018       2019       2018    
                     
                     
  Operating expenses     29,300       22,099       56,634       37,671    
  Adjustments:                  
  Stock-based compensation     (2,323 )     (1,137 )     (3,907 )     (1,734 )  
  Contingent consideration fair value adjustment     -       (100 )     (289 )     (100 )  
  Litigation-related expenses     (1,200 )     (2,234 )     (3,823 )     (2,814 )  
  Restructuring     -       (193 )     (60 )     (591 )  
  Transaction-related expenses     -       62       -       (1,480 )  
  Gain on settlement     -       -       -       6,168    
  Non-GAAP operating expenses   $ 25,777     $ 18,497     $ 48,555     $ 37,120    
                     
                     
      Three Months Ended   Six Months Ended  
      June 30,   June 30,  
        2019       2018       2019       2018    
                     
  Operating loss, as reported   $ (10,414 )   $ (6,545 )   $ (21,180 )   $ (7,212 )  
  Add back significant items:                  
  Stock-based compensation     2,351       1,148       3,963       1,767    
  Contingent consideration fair value adjustment     -       100       289       100    
  Litigation-related expenses     1,200       2,234       3,823       2,814    
  Restructuring     -       193       60       591    
  Transaction-related expenses     -       (62 )     -       1,480    
  Excess & obsolete charges     2,200       354       4,175       1,272    
  Gain on settlement     -       -       -       (6,168 )  
  Non-GAAP operating loss     (4,663 )     (2,578 )     (8,870 )     (5,356 )  
                     
                     
  Operating loss, as reported   $ (10,414 )   $ (6,545 )   $ (21,180 )   $ (7,212 )  
  Depreciation     1,473       1,457       3,076       3,049    
  Amortization of intangible assets     172       132       354       426    
  EBITDA     (8,769 )     (4,956 )     (17,750 )     (3,737 )  
  Add back significant items:                  
  Stock-based compensation     2,351       1,148       3,963       1,767    
  Contingent consideration fair value adjustment     -       100       289       100    
  Litigation-related expenses     1,2a00       2,234       3,823       2,814    
  Restructuring     -       193       60       591    
  Transaction-related expenses     -       (62 )     -       1,480    
  Excess & obsolete charges     2,200       354       4,175       1,272    
  Gain on settlement     -       -       -       (6,168 )  
  Non-GAAP adjusted EBITDA   $ (3,018 )   $ (989 )   $ (5,440 )   $ (1,881 )  
                     


ALPHATEC HOLDINGS, INC.  
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS PROFIT  
(in thousands, except percentages - unaudited)  
                   
                   
    Three Months Ended   Six Months Ended  
    June 30,   June 30,  
      2019       2018       2019       2018    
  Revenues by source                
  Revenue from U.S. products $ 26,093     $ 20,409     $ 49,048     $ 39,610    
  Revenue from international supply agreement   1,226       1,633       2,826       3,739    
  Total revenues $ 27,319     $ 22,042     $ 51,874     $ 43,349    
                   
  Gross profit by source                
  Revenue from U.S. products $ 18,841     $ 15,462     $ 35,235     $ 30,229    
  Revenue from international supply agreement   45       92       219       230    
  Total gross profit $ 18,886     $ 15,554     $ 35,454     $ 30,459    
                   
  Gross profit margin by source                
  Revenue from U.S. products   72.2%       75.8%       71.8%       76.3%    
  Revenue from international supply agreement   3.7%       5.6%       7.7%       6.2%    
  Total gross profit margin   69.1%       70.6%       68.3%       70.3%    
                   
                   
  RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND GROSS MARGIN FROM U.S. PRODUCTS
(in thousands, except percentages - unaudited)  
                   
    Three Months Ended   Six Months Ended  
    June 30,   June 30,  
      2019       2018       2019       2018    
                   
  GAAP-based gross profit from U.S. products $ 18,841     $ 15,462     $ 35,235     $ 30,229    
  Add: non-cash excess and obsolete charges   2,200       354       4,175       1,272    
  Non-GAAP gross profit from U.S. products $ 21,041     $ 15,816     $ 39,410     $ 31,501    
                   
  GAAP-based gross margin from U.S. products   72.2%       75.8%       71.8%       76.3%    
  Add: non-cash excess and obsolete charges   8.4%       1.7%       8.5%       3.2%    
  Non-GAAP gross margin from U.S. products   80.6%       77.5%       80.3%       79.5%